Entos, Inc., the developer of a cutting-edge platform that combines AI-driven technology and automated synthetic development to design small-molecule therapeutics, has closed a $53 million Series A financing.
The round led by Coatue, a leading technology investment firm, and Catalio Capital Management, a leading biomedical technology investment firm, with participation from OrbiMed.
Company: Entos Inc.
Round: Series A
Funding Month: July 2021
Lead Investors: Coatue and Catalio Capital Management
Additional Investors: OrbiMed
Company Website: https://www.entos.ai/
Software Category: a cutting-edge platform >AI
About the Company: The company was founded in 2019 and is based in San Diego, California. Orbed, Entos' cutting-edge platform that combines AI-driven technology and automated synthetic development to swiftly generate small-molecule therapies, is focused on disrupting therapeutic discovery. Entos' team is made up of renowned scientists and engineers – including Chemistry Nobel Prize winner Frances Arnold – with world-class expertise in machine learning and software development, as well as computational and medicinal chemistry, and is powered by technology developed at Caltech and the University of Bristol.